top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hLUCA2 mice
Strain Name
C57BL/6N-Luca2tm1(LUCA2)Bcgen/Bcgen
Common Name  B-hLUCA2 mice
Background C57BL/6N Catalog number 112499
Aliases 
Human: HYAL2

Description



  • HYAL2, a glycosylphosphatidylinositol (GPI)-anchored membrane receptor, binds and cleaves HMW-HA into low molecular-weight HA (LMW-HA; ~ 20 kDa) fragments at the cell membrane. This mechanism has been proposed to require the presence and activity of the major HA receptor CD44, which is essential for intracellular signaling. Inside lysosomes, HA is further processed into oligomeric HA fragments by HYAL1, together with exoglycosidases.
  • Hyaluronidase (HYAL)-2 has been identified as one of the principal enzymes involved in HA catabolism in vertebrates. HYAL2 is broadly expressed in tissues but has catabolic function within only a narrow acidic pH range (optimal pH, 4), and compared to other HYALs, has only weak intrinsic HA-degrading activity. 
  • HYAL2 was originally identified as a lysosomal enzyme but was also subsequently identified as anchored to the cell membrane via a glycosylphosphatidylinositol link.15 Aberrant expression of HYAL2 is implicated in diverse pathology, including cardiac and skeletal abnormalities, hematopoietic and platelet dysfunction, cancer, and fibrosis.




Mechanism of action

from clipboard
Proposed model of HA degradation. HA degradation occurs through more than one pathway, each indicated by different numbers, 1–4, in this model. 
In pathway 1, cell surface HYAL2 initiates the hydrolysis of HA in partnership with a receptor, possibly CD44. NHE1 acidifies the local region to allow HYAL2 cleavage. The resulting HA fragments are endocytosed and transported to the lysosome (Lys) where they are degraded through the action of the endoglycosidase HYAL1 and the exoglycosidases, β-hexosaminidase (HEX) and β-glucuronidase (GLUC). 
In pathway 2, secretory vesicles (SV) within specialized epithelial cells are surrounded by HYAL2. Upon secretion, these vesicles will degrade extracellular HA. 
In pathway 3, cell surface HYAL2 is shed from the surface or released through by a lipase or protease to form a soluble form of HYAL2. This enzyme can enter the blood stream or diffuse from the surface to degrade HA distal from the site of HYAL2 expression.
In pathway 4, HA is internalized by a non-HYAL2-dependent route and transported to the lysosome for degradation.

Targeting strategy



Gene targeting strategy for B-hLUCA2 mice. 
The exons 2~4 of mouse Luca2 gene that encode the full-length protein were replaced by human LUCA2 exons 2~4 in B-hLUCA2 mice. 


Model validation


from clipboard

Protein expression analysis

from clipboard


Western blot analysis of LUCA2 protein expression in homozygous B-hLUCA2 mice. Various tissue lysates were collected from C57BL/6N wildtype mice (+/+) and homozygous B-hLUCA2 mice (H/H), and then analyzed by western blot with anti-LUCA2 antibody. 40 μg total proteins were loaded for western blotting analysis. LUCA2 was detected in stomach, testis, lung, spleen, liver and skeletal muscle in wild-type C57BL/6N mice and homozygous B-hLUCA2 mice.


mRNA expression analysis


from clipboard


Strain specific analysis of LUCA2 mRNA expression in wild-type C57BL/6 mice and B-hLUCA2 mice by RT-PCR. Kidney RNA were isolated from wildtype C57BL/6 mice (+/+) and homozygous B-hLUCA2 mice (H/H), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse or human LUCA2 primers. Mouse Luca2 mRNA was detectable only in wild-type C57BL/6 mice. Human LUCA2 mRNA was detectable only in homozygous B-hLUCA2 mice but not in wild-type mice.


Summary


Protein expression analysis:
LUCA2 protein was detected in stomach, testis, lung, spleen, liver and skeletal muscle of wild-type C57BL/6 mice and homozygous B-hLUCA2 mice.